โšกToday
โœจToday's leadDoctors Complete First Bone Marrow Transplant From Deceased Donor for Non-Malignant Disease๐ŸŽˆFor kidsSouth Carolina tract beside wildlife refuge to be permanently conserved๐ŸŒฟNatureFormer ocean liner S.S. United States becomes the world's largest artificial reefโšฝSportsLindy Duncan wins her first LPGA title on attempt 222๐ŸŽจCulture & ideasA Lost Altdorfer Landscape Surfaces After 70 Years Privately Held๐Ÿ”ฌScience & healthPeople who control HIV without treatment may help find a cure๐Ÿ’›KindnessA laid-off man began mowing lawns for free and 2,100 volunteers joined๐Ÿ›๏ธPoliticsLos Angeles bans oil drilling after a decade of neighborhood pressure๐Ÿš€ProgressPhiladelphia repaired a collapsed interstate in 12 days

Once-Daily Pill Shows Promise for Ulcerative Colitis

Forbes 11 November 2026 2 min read

โฎ BeforePatients usually receive ulcerative colitis drugs by injection or infusion.
โœ… NowA once-daily oral peptide improved response and remission rates in a phase 2 trial.

In short

  • The once-daily oral peptide improved ulcerative colitis response and remission rates in a phase 2 trial.
  • It is a potential alternative to injections or infusions.
  • The result is from a phase 2 trial, so larger studies are still needed.

Why it's good news

Ulcerative colitis is a long-term condition that often needs regular treatment. The current options often involve injections or intravenous infusions. This phase 2 trial suggests a daily oral peptide could help patients reach response and remission, but it is still at an early stage.

Advertisement

From Forbes

A once-daily oral peptide improved ulcerative colitis response and remission rates in a phase 2 trial, offering a potential alternative to injections or infusions.

Read the full story at Forbes Opens the publisher's site in a new tab.

Ask this story

An AI model answers from the material behind this story only, with a link to the source. Your question is sent to our AI provider and isn't stored. See Privacy.

More like this

Advertisement
AdMobile anchor